Although interesting, this information isn't very useful in its implications for Bristol's revenue and resulting share price without the number of people who fall under the specific trial inclusion criteria. The treatment field for prostate cancer is much more complicated than melanoma due to the number of effective treatments available, including surgery. It is also clouded by the fact that Ipi can have severe side effects, including death (all IMHO).
Can't give you specifics on that subset of Prostate Cancer Patients but know it is the second leading cause of Cancer Death for Men after Lung Cancer with I believe (this is from memory but I think pretty close) around 25,000 deaths per year in US which is about three times the about 8,000 annual m melanoma deaths per year US. BMY has also begun a 800 patient Phase III in Lung Cancer which is #1 in yearly US deaths at +65,000 . Thats why it's so hard to estimate the future size of the Ipi market which may be 1 or 2 billion in Melanoma / add prostate quadruple those #s add lung the biggest cancer drug based on revenues in the world. But of course we have to wait for clinical results.
This is the following subset of prostate cancer patients: prior radiotherapy with castration resistant prostate cancer that have received prior treatment with docetaxel. If completed as scheduled in Dec 2012 with BLA submission in mid-late 2013, the PDUFA date will be early-mid 2014. Any idea of the size of this patient population? (all IMHO).